Cell No. 4 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Cell No. 4 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Press Releases

August 1, 2019

Viracta Strengthens Executive Management Team with New Appointments

Viracta Therapeutics, Inc. announced today that it has appointed Dan Chevallard as Chief Financial Officer and Xiaohu Deng, Ph.D. as Senior Vice President of Product Development. Read More | PDF

June 3, 2019

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting

Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion of the ongoing Phase 1b/2 clinical trial of nanatinostat in combination with the antiviral valganciclovir for the treatment of relapsed/refractory EBV-associated lymphomas. Read More | PDF

May 15, 2019

Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting

Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL. Read More | PDF | PDF

April 16, 2019

Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers

Viracta Therapeutics, Inc. announced today that the U. S. Food & Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to their Phase 2 drug candidate, nanatinostat, in combination with the antiviral valganciclovir, for the treatment of post-transplant lymphoproliferative disorder (PTLD), plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Read More | PDF

December 4, 2018

Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China

Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a financing, with Salubris committing $10 million as the lead investor. Read More | PDF

September 25, 2018

Viracta Announces Scientific Advisory Board Formation

Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, announced the formation of its inaugural Scientific Advisory Board. Read More

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat

San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

April 4, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership

Culver City and San Diego, April 4, 2017 - NantKwest, Inc. [NASDAQ:NK] and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Read More

January 9, 2017

BioCentury - Viral Vulnerability

Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that make cancerous cells vulnerable to antiviral treatment. Read More

November 30, 2016

Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics

San Diego and London; November 30, 2016 – Viracta Therapeutics, Inc. announced completion of its acquisition of drug development candidate, VRx-3996, from Chroma Therapeutics, Ltd. Viracta plans to advance VRx-3996 (previously CHR-3996) into Phase 2 clinical testing for application in Viracta’s proprietary anticancer combination therapy approach. The Company will initially focus on Epstein Barr Virus-associated lymphoid malignancies. Read More

Events

June 19-21, 2019

Viracta will be doing a poster presentation at the 2019 ICML meeting in Lugano. Read More

May 31-June 4, 2019

Some of the team will be attending the Chicago, IL ASCO Meeting. Read More

May 29, 2019

Our CEO, Dr. Ivor Royston, will be winning a lifetime achievement award at the upcoming Xconomy San Diego Awards Gala. Read More

April 18, 2019

Join our CEO, Dr. Ivor Royston, for a Rady School guest lecture on “Fostering Medical Innovation: Reflections from an Academic Physician, Entrepreneur, Venture Capitalist, and Biotech CEO”. Read More

Media

Lessons from a One Eyed Surgeon with Clifton Leaf

Now CEO of Viracta, Ivor Royston introducing Clifton Leaf to walk through the story of Denis Burkitt and the discovery of the first virus associated with human cancer - Epstein Barr Virus.

Press Releases

August 1, 2019

Viracta Strengthens Executive Management Team with New Appointments

Viracta Therapeutics, Inc. announced today that it has appointed Dan Chevallard as Chief Financial Officer and Xiaohu Deng, Ph.D. as Senior Vice President of Product Development. Read More | PDF

June 3, 2019

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting

Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion of the ongoing Phase 1b/2 clinical trial of nanatinostat in combination with the antiviral valganciclovir for the treatment of relapsed/refractory EBV-associated lymphomas. Read More | PDF

May 15, 2019

Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting

Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL. Read More | PDF

April 16, 2019

Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers

Viracta Therapeutics, Inc. announced today that the U. S. Food & Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to their Phase 2 drug candidate, nanatinostat, in combination with the antiviral valganciclovir, for the treatment of post-transplant lymphoproliferative disorder (PTLD), plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Read More | PDF

December 4, 2018

Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China

Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a financing, with Salubris committing $10 million as the lead investor. Read More | PDF

September 25, 2018

Viracta Announces Scientific Advisory Board Formation

Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, announced the formation of its inaugural Scientific Advisory Board. Read More

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat

San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

April 4, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership

Culver City and San Diego, April 4, 2017 - NantKwest, Inc. [NASDAQ:NK] and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Read More

January 9, 2017

BioCentury - Viral Vulnerability

Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that make cancerous cells vulnerable to antiviral treatment. Read More

November 30, 2016

Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics

San Diego and London; November 30, 2016 – Viracta Therapeutics, Inc. announced completion of its acquisition of drug development candidate, VRx-3996, from Chroma Therapeutics, Ltd. Viracta plans to advance VRx-3996 (previously CHR-3996) into Phase 2 clinical testing for application in Viracta’s proprietary anticancer combination therapy approach. The Company will initially focus on Epstein Barr Virus-associated lymphoid malignancies. Read More

Events

June 19-21, 2019

Viracta will be doing a poster presentation at the 2019 ICML meeting in Lugano. Read More

May 31-June 4, 2019

Some of the team will be attending the Chicago, IL ASCO Meeting. Read More

May 29, 2019

Our CEO, Dr. Ivor Royston, will be winning a lifetime achievement award at the upcoming Xconomy San Diego Awards Gala. Read More

April 18, 2019

Join our CEO, Dr. Ivor Royston, for a Rady School guest lecture on “Fostering Medical Innovation: Reflections from an Academic Physician, Entrepreneur, Venture Capitalist, and Biotech CEO”. Read More

Media

Lessons from a One Eyed Surgeon with Clifton Leaf

Now CEO of Viracta, Ivor Royston introducing Clifton Leaf to walk through the story of Denis Burkitt and the discovery of the first virus associated with human cancer - Epstein Barr Virus.

Publications

Viracta presents a poster at the 2019 ICML meeting in Lugano - A Phase Ib/II Study of Oral Nanatinostat (Nstat) and Valganciclovir (VG) in Patients with Epstein-Barr Virus (EBV)-associated Lymphomas - Please click here to view the poster

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - Please click here to view the poster

A Phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies, Perrine, Hermine, Small, Suarez, O’Reilly, Boulad, Fingeroth, Askin, Levy, Mentzer, Di Nicola, Gianni, Klein, Horwitz and Faller et al, Blood, 109: 2571-2578, 2007.

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents, Ghosh, Perrine, Williams and Faller et al, Blood, 119: 1008—1017, 2012.

A phase 1 pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class 1 selective histone deacetylase inhibitor in refractory solid tumors, Banerji, van Doorn, Papadotos-Pastos, Kristeleit, Debnam, Tall, Stewart, Raynaud, Garrett, Toal, Hooftman, De Bono, Verweij, Eskens et al, Cancer Clinical Research, 18: 2687-2694, 2012.

Discovery of 2-(6-{[6-fluoroquinolin-2-yl)methyl]amino}bicycle[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5carboxamide (CHR-3996), a class 1 selective orally active histone deacetylase inhibitor, Moffat, Patel, Day, Belfield, Donald, Rowlands, Wibawa, Brotherton, Stimson, Clark, Owen, Bawden, Box, Bone, Mortenson, Hardcastle, van Meurs, Eccles, Raynaud, Aherne et al, Journal of Medicinal Chemistry, 132: 114367-14369, 2010.